Acute Ischemic Stroke Clinical Trial
Official title:
The Influence of Different Hemodynamic Parameters in First 24 Hours After Intravenous Thrombolysis on Acute Ischemic Stroke Outcomes: A Randomised Clinical Trial
The investigators are suggtesting that lower goals of systolic blood pressure after intravenous thrombolysis may reduce the risk of hemorrhagic complications and improve functional outcomes after acute ischemic stroke.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | January 10, 2025 |
Est. primary completion date | January 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion ?riteria: - ischemic stroke diagnosis - performed intravenous thrombolysis (including "wake up stroke") - systolic blood pressure >140 mmHg - informed consent or council of physician agreement Exclusion criteria: - absence of informed consent or council of physician agreement - pregnancy - patients participainting in other clinical trial in the last 90 days - any absolute contraindications to intravenous thrombolysis ?ompletion criteria: - failure to achieve hemodynamic goal for 20 minutes before the start of intravenous thrombolysis - failure to achieve hemodynamic goal for 60 minutes in first 24 hours after intravenous thrombolysis - relative arterial hypotension (SBP <100 mmHg for 60 minutes in first 24 hours after intravenous thrombolysis) - unfavorable effect development (e.g. seizures, angioedema) - informed consent is retracted |
Country | Name | City | State |
---|---|---|---|
Russian Federation | City Hospital # 1 n.a. E.E. Volosevich | Arkhangelsk |
Lead Sponsor | Collaborator |
---|---|
Northern State Medical University |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Modified Rankin Scale score | Fucntional outcome (Modified Rankin Scale) will be assesed by telephone interview. Score from 0 to 6. Higher scores mean a worse outcome. | 90 day after intravenous thrombolysis | |
Primary | Mortality rate | At 90 day after intravenous thrombolysis | ||
Primary | Rate of symptomatic intracranial hemorrhage | Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH | 24 hours after intravenous thrombolysis | |
Primary | Rate of symptomatic intracranial hemorrhage | Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH | 7 days after intravenous thrombolysis | |
Secondary | Change in National Institutes of Health Stroke Scale (NIHSS) | Score form 0 to 42. Higher score indicates worse outcome | at 28 day after intravenous thrombolysis | |
Secondary | Rate of all Intracranial hemorrhage | Intracranial hemorrhage will be classified according to Heidelberg bleeding classification | 24 hours after intravenous thrombolysis | |
Secondary | Rate of all Intracranial hemorrhage | Intracranial hemorrhage will be classified according to Heidelberg bleeding classification | 7 days after intravenous thrombolysis | |
Secondary | Lengths of stay in ICU | at 90 day after intravenous thrombolysis | ||
Secondary | Lengths of stay in hospital | at 90 day after intravenous thrombolysis | ||
Secondary | Rate of acute kidney injury | Acute kidney injury will be assesed according to RIFLE Classification | 28 day after intravenous thrombolysis or at discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |